



IHH Healthcare Berhad

Kuala Lumpur/Singapore, 9 December 2019

Strong shareholder support in favour of Prince Court Medical Centre transaction; IHH set to complete deal by Q1 2020 and strengthen leadership position in Malaysia

HIGHLIGHTS:

Shareholders vote in favour of transaction

- Near unanimous support from non-interested shareholders and proxies in favour of proposed acquisition of Prince Court Medical Centre (“PCMC”), for cash consideration of RM1.02 billion

IHH to strengthen market position, better serve patients in Malaysia through PCMC addition

- Strategically located in the “Golden Triangle” area of Kuala Lumpur, PCMC will allow IHH to broaden its service offerings, deepen its clinical talent pool and strengthen its position in the foreign patient segment of the market
- PCMC is a profitable private healthcare facility, and is expected to enhance the Group’s revenue and income stream, and contribute to its long-term growth

IHH Healthcare Berhad (“IHH” or the “Group”), a leading premium global healthcare provider, has secured strong shareholder approval for its proposed acquisition of Prince Court Medical Centre (“PCMC”). This moves the Group closer to strengthening its market position in Malaysia and allowing it to better serve patient needs in the country.

At an extraordinary general meeting today, more than 99.99% of non-interested IHH shareholders and proxies voted in favour of the conditional share purchase agreement between IHH’s wholly-owned subsidiary, Pantai Holdings Sdn Bhd, and Pulau Memutik Ventures Sdn Bhd, a wholly-owned subsidiary of Khazanah Nasional Berhad, for the acquisition of the entire issued share capital of PCMC, for a cash consideration of RM1.02 billion.

Barring unforeseen circumstances and pending regulatory approvals, IHH expects the proposed acquisition to be completed in the first quarter of 2020.

Strategically located in the “Golden Triangle” area of Kuala Lumpur, Malaysia, PCMC is a 277-licensed bed private healthcare facility offering a wide range of services including, among others, burns management, cancer, gastrointestinal diseases, interventional cardiology, in vitro fertilisation, nephrology, occupational health, orthopaedic and rehabilitation medicine. It is a profitable operation that is expected to enhance the Group’s revenue and income stream, and contribute to its long-term growth.

The proposed acquisition of PCMC is aligned with IHH’s commitment to provide the highest standards of care and clinical outcomes that patients can trust, across its network of healthcare facilities. Once the transaction is completed, PCMC will become the Group’s 16th hospital in Malaysia.

Mr Joe Sim, Chief Executive Officer, Malaysia Operations Division, IHH, said, “Adding Prince Court Medical Centre will empower us to bring our best-in-class care and outcomes to even more patients in Malaysia and aboard. With a broader network and stronger cluster of specialised tertiary hospitals in the Klang Valley, supported by a deeper clinical talent pool, IHH can offer a wider array of services and take on more complex cases. This will make our facilities even more compelling for both local and foreign patients, and further reinforces Malaysia’s attractiveness as a medical travel destination.”

Datuk Dr Kuljit Singh, Medical Director at Prince Court Medical Centre and President of the Association of Private Hospitals Malaysia, said, “We look forward to build upon Prince Court’s success and work closely with the management team of IHH to further grow the business. As part of the IHH Group, Prince Court Medial Centre can leverage on its scale and track record to unlock greater synergies and enhance our suite of service offerings and delivery of value-based care. This will enable us to better serve patients’ needs optimally together and create sustainable growth.”

For further information or to speak to an IHH spokesperson, please contact:

Penelope Koh
t. +65 6307 7881

e. penelope.koh@ihhhealthcare.com

Ong Chor Hao
t. +65 9672 2674

e. chorhao@we-watatawa.com

About IHH Healthcare Berhad (“IHH”)

IHH Healthcare Berhad is a leading premium integrated healthcare provider in markets where the demand for quality care is strong and growing. We are one of the largest healthcare groups in the world by market capitalisation and are listed on the Main Market of Bursa Malaysia and the Main Board of SGX-ST.

Employing more than 55,000 people and operating over 15,000 licensed beds across 80 hospitals in 10 countries worldwide, the Group offers the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services across our operating subsidiaries:

- **Parkway Pantai Limited** is one of Asia's largest integrated private healthcare groups with a network of 29 hospitals throughout the region, including Malaysia, Singapore, India, China, Brunei and UAE. Its “Mount Elizabeth”, “Gleneagles”, “Parkway” and “Pantai” brands are among the most prestigious in Asia.
- **Acibadem Holdings** is Turkey’s leading private healthcare provider, offering integrated healthcare services across 22 hospitals in Turkey, Macedonia, Bulgaria and Amsterdam. The “Acibadem” brand is renowned for its clinical excellence in the Central & Eastern Europe, Middle East and North Africa (“CEEMENA”) region.
- **Fortis Healthcare Limited** is a leading integrated private healthcare provider in India. It operates across a network of 32 healthcare facilities and 378 diagnostic centres in India, Dubai, Mauritius and Sri Lanka. Fortis is listed on the Bombay Stock Exchange.
- **IMU Health** is IHH’s medical education arm, and oversees the established higher learning institutions of International Medical College (“IMC”) and International Medical University (“IMU”) in Malaysia.

IHH is the leading player in our home markets of Malaysia, Singapore, Turkey and India, and key growth market of Greater China (including Hong Kong). For more information, please visit www.ihhhealthcare.com.